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Objectives The purpose of this study was to compare the safety and efficacy of acetylsalicylic acid (ASA) and warfarin for
thromboprophylaxis after the Fontan procedure.
Background Fontan surgery is the definitive palliation for children with single-ventricle physiology. Thrombosis is an important
complication; the optimal thromboprophylaxis strategy has not been determined.
Methods We performed a multicenter international randomized trial of primary prophylactic anticoagulation after Fontan
surgery. Patients were randomized to receive for 2 years either ASA (5 mg/kg/day, no heparin phase) or warfa-
rin (started within 24 h of heparin lead-in; target international normalized ratio: 2.0 to 3.0). Primary endpoint
(intention to treat) was thrombosis, intracardiac or embolic (all events adjudicated). At 3 months and 2 years
after the Fontan procedure, transthoracic and transesophageal echocardiograms were obtained as routine sur-
veillance. Major bleeding and death were primary adverse outcomes.
Results A total of 111 eligible patients were randomized (57 to ASA, 54 to heparin/warfarin). Baseline characteristics for each
group were similar. There were 2 deaths unrelated to thrombosis or bleeding. There were 13 thromboses in the heparin/
warfarin group (3 clinical, 10 routine echo) and 12 thromboses in the ASA group (4 clinical, 8 routine echo). Overall free-
dom from thrombosis 2 years after Fontan surgery was 19%, despite thrombosis prophylaxis. Cumulative risk of thrombo-
sis was persistent but varying and similar for both groups (p 0.45). Major bleeding occurred in 1 patient in each group.
Conclusions There was no significant difference between ASA and heparin/warfarin as primary thromboprophylaxis in the
first 2 years after Fontan surgery. The thrombosis rate was suboptimal for both regimens, suggesting alternative
approaches should be considered. (International Multi Centre Randomized Clinical Trial Of Anticoagulation In
Children Following Fontan Procedures; NCT00182104) (J Am Coll Cardiol 2011;58:645–51) © 2011 by the
American College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2011.01.061Fontan surgery, first performed for tricuspid atresia in the
late 1960s, has evolved as the definitive palliative surgery for
all children with univentricular cardiac physiology, irrespec-
tive of whether they have a functioning right, left, or
indeterminate ventricle. The Fontan principle is diversion of
systemic venous return directly to the pulmonary arteries,
and the use of the single ventricle as a functioning systemic
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dren after Fontan surgery; hence,
the frequency of Fontan surgery
continues to increase (5–7).
Thrombosis remains a major
complication after Fontan sur-
gery, presenting as intracardiac
or intravascular thrombosis, cere-
brovascular thromboembolism,
or other embolic phenomena. The true frequency of throm-
bembolism post-Fontan surgery remains unknown (1,8).
Cross-sectional surveys using transesophageal echocardiog-
raphy (TEE) reported a prevalence of intracardiac throm-
bosis of 17% to 33% (9–11). Cohort studies that had venous
thrombosis or arterial emboli (or both) as a primary out-
come measure reported incidences of venous thrombosis
ranging from 3% to 19% and the incidence of stroke ranging
from 3% to 19%, depending on the nature of the cohort and
the duration and nature of follow-up. The reported mortal-
ity from post-Fontan surgery thromboembolism is 25% (1).
In this context, a multitude of primary thromboprophylaxis
strategies have been suggested. However, there have been
no prospective data on which to base any prophylactic
protocols (12,13).
We performed a multicenter, randomized, controlled trial of
primary prophylactic anticoagulation after Fontan surgery,
comparing 2 commonly used strategies, to determine their
efficacy and safety in the first 2 years after Fontan surgery.
Methods
Study subjects. All patients scheduled for a Fontan proce-
dure were eligible for inclusion. Exclusion criteria included
the presence of a recognized indication for long-term
anticoagulation; characteristics associated with an increased
risk of bleeding; known medical contraindication to hepa-
rin, warfarin, or acetylsalicylic acid (ASA); inability to
supervise therapy due to social or geographic reasons; and
pregnancy or potential pregnancy during the study period.
Randomization. Randomization was performed centrally
immediately after completion of the Fontan procedure.
Randomization was stratified by center.
Study intervention. The study interventions were deliv-
ered in accordance with standard protocols for a 2-year
period. Subjects randomized to warfarin received heparin
initially at a dose of 10 to 20 U/kg/h. Usually within 24 h of
starting heparin and when the patient was first able to
tolerate oral medication, a loading dose of warfarin of 0.1
mg/kg was given. The dose was then titrated to achieve a
target international normalized ratio (INR) of 2.0 to 3.0,
and heparin was discontinued when the INR first reached
2.0. Adjustment of the maintenance dose of warfarin was
dependent on INR monitoring as follows: INR of 2.0 to 3.0,
no change in dose; INR of 1.1 to 1.4, increase dose by 20%;
INR of 1.5 to 1.9, increase dose by 10%; INR of 3.1 to 3.5,
Abbreviations
and Acronyms
ASA  acetylsalicylic acid
INR  international
normalized ratio
TEE  transesophageal
echocardiographydecrease dose by 10%; and INR of3.5, hold warfarin until tINR was 3.5, then decrease dose by 20% when restarted.
Patients randomized to ASA were started when they were
tolerating any oral intake (ASA, 5 mg/kg/day, no heparin
phase, no monitoring). Because Fontan patients are well
documented to be at an important risk of thrombotic
complications, there was believed to be insufficient clinical
equipoise to include a nonintervention group.
Measurements. Study measurements included a baseline
medical record review to abstract data regarding demo-
graphics, underlying cardiac anatomy, previous interven-
tions and complications, and previous and current medical
therapy. Data regarding the Fontan procedure and post-
operative complications were collected. Clinical monitoring
was performed at 3, 6, 12, 18, and 24 months after
randomization and whenever it was clinically indicated.
INR monitoring and dose adjustments for warfarin to
maintain the patient within the therapeutic range were the
responsibility of the treating center and were dependent on
the clinical status of the child. INR monitoring was pre-
scribed to be performed at least every 2 to 3 weeks for stable
patients and more frequently for patients with dosing
challenges. Routine transthoracic echocardiography and
TEE was performed at 3 and 24 months post-Fontan
surgery. All patients were requested to attend all study visits
regardless of whether they were still taking their assigned
study medication and/or had reached a study outcome.
Thrombosis with clinical presentation, severe bleeding com-
plications, Fontan takedown, death, and all other serious
adverse events were captured for all patients.
Blinding. All medication use was open label. Local echo-
cardiographic assessments were performed by sonographers
and echocardiographers in a blinded manner. There was an
independent central adjudication of clinically driven and
routine echocardiograms. All thrombosis and major adverse
clinical events were adjudicated by an expert panel.
Study endpoints. The primary endpoint was any throm-
botic event (venous or arterial). This was defined as the
ultrasound appearance of a space-occupying lesion within
the cardiovascular system (mild laminar thickening of the
internal surface of the Fontan pathway was not included)
or the occurrence of a clinical event known to be strongly
associated with thrombus (cardioembolic stroke, pulmo-
nary embolism). Additional endpoints included Fontan
takedown, death, and study drug discontinuation or
crossover.
Statistics. Data are described as mean  SD, median
minimum, maximum values), or frequencies as appropriate.
ifferences between groups were assessed using the Student
test with Satterthwaite correction for variance estimation
nd the Fisher exact chi-square test. Timed-event analysis
f thrombosis after randomization was modeled using
onparametric Kaplan-Meier estimates with a log-rank test
or group comparison. Timed-event analyses were per-
ormed twice, once with patients being censored at the time
rug discontinuation and once with censoring only at study
ermination. All analyses were based on an intention-to-
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version 9.1 (SAS Institute, Cary, North Carolina).
Results
Enrollment and patient population. Patients were re-
cruited from 6 institutions from 1998 through 2003. During
that time, 242 patients were scheduled for Fontan surgery,
of whom 111 were eventually enrolled and randomized, 57
to ASA and 54 to warfarin. All randomized patients were
included in the final analysis (Fig. 1).
Patient baseline characteristics. Baseline characteristics
were similar between groups regarding demographics and
underlying cardiac diagnoses. Previous thrombosis before
Fontan surgery was equally prevalent in both groups. There
were no differences in pre-operative characteristics or he-
modynamics. The groups were similar regarding age at
Fontan surgery, with the majority having extracardiac con-
duits and being fenestrated. There were no differences in
perioperative or post-operative variables, including length of
hospital stay and laboratory values (Table 1).
Compliance with study intervention and assessments.
Patients taking ASA completed 92% of days on the study
drug, and patients taking warfarin completed 84% of days
(p  0.02). Early discontinuations of the study drug were
ore frequent in the warfarin group (19% vs. 9%). Com-
liance with undergoing TEE was good, with 81% of
atients undergoing TEE at least once (69% undergoing
-month TEE, 61% undergoing 24-month TEE) and 48%
ndergoing both TEE protocols. A total of 3 patients
rematurely withdrew from the study (2 receiving warfarin,
Figure 1 Study Screening and Enrollment
Of 242 patients screened, 208 were eligible for the trial of whom 111 were
eventually randomized. Of the 111 patients randomized, 54 (49%) were ran-
domized to warfarin and 57 (51%) were randomized to acetylsalicylic acid.
A/C  anticoagulation.areceiving ASA). One patient died due to massive cerebral
emorrhage secondary to low cardiac output syndrome early
n the study. This patient was assigned to but had not yet
eceived ASA at the time of death (Table 2). Overall, 95%
f patients attended all 5 study assessments, and complete
Patient CharacteristicsTable 1 Patient Characteristics
ASA
(n  57)
Warfarin
(n  54)
Demographics
Male 34 (60%) 37 (69%)
Age at Fontan surgery, yrs 4.6 2.3 5.1 3.4
Weight at date of surgery, kg 16.5 4.4 18.1 9.3
Major cardiac defect
Tricuspid atresia 11 (19%) 10 (19%)
Double inlet left ventricle 13 (23%) 8 (15%)
Double outlet right ventricle 4 (7%) 8 (15%)
Pulmonary atresia and
intact ventricular septum
1 (2%) 5 (9%)
Unbalanced atrioventricular septal defect 4 (7%) 6 (11%)
Hypoplastic left heart 8 (14%) 9 (17%)
Ebstein’s anomaly 1 (2%) 1 (2%)
Other/multiple anomalies 15 (26%) 7 (13%)
Previous cardiac surgical procedures
(not mutually exclusive)
Cardiac catheter/interventional procedures 32 (56%) 31 (57%)
Norwood operation 11 (19%) 13 (24%)
Damus-Kaye-Stansell procedure
(for subaortic stenosis)
8 (14%) 8 (15%)
Bidirectional cavopulmonary shunt 40 (70%) 40 (74%)
Bilateral cavopulmonary shunt 7 (12%) 8 (15%)
Aortic coarctation repair 5 (9%) 3 (6%)
Other cardiac surgical procedures 21 (37%) 24 (44%)
Thrombosis history
Patient has a previous thrombotic event 10 (18%) 5 (9%)
Years (range) since last event 2.4 (0.3–4.3) 2.2 (1.2–2.9)
On anticoagulation within 7 days of
randomization
6 (11%) 2 (4%)
Fontan procedure
Type of Fontan procedure: extracardiac
conduit vs. lateral tunnel
49 (86%) 46 (85%)
Type of baffle or conduit used:
GORE-TEX vs. homograft
43 (75%) 38 (70%)
Size of baffle or conduit used, mm [54] 19 3 [47] 19 4
Fenestration 37 (65%) 32 (59%)
Size of fenestration used, mm [35] 4.8 2.0 [32] 4.3 1.3
Concurrent procedures 25 (44%) 29 (54%)
Perioperative characteristics
Cardiopulmonary bypass time, min (range) 96 (29–307) 104 (11–313)
Aortic cross-clamping used 19 (33%) 22 (41%)
Circulatory arrest used 2 (4%) 2 (4%)
Reoperation
Bleeding 1 (2%) 1 (2%)
Delayed sternal closure 1 (2%) 2 (4%)
Open/close fenestration 2 (4%) 1 (2%)
Revise Fontan connections 3 (5%) 1 (2%)
Thrombosis 0 (0%) 1 (2%)
Values are n (%), mean  SD, or median (minimum–maximum). Numbers in square brackets
represent available sample size if there are any missing values.
ASA  acetylsalicylic acid.ccrual of clinical events was obtained.
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21% of patients receiving ASA and 24% of those receiving
warfarin during the full duration of the study (Fig. 2). On
Kaplan-Meier analysis, the estimate of the proportion of
patients who had a thrombosis event at 2 years (including all
patients, intention to treat) was 19% overall, with no
significant differences between warfarin and ASA (24% vs.
14%, p  0.45) (Fig. 3). The magnitude of the difference
was further reduced with inclusion of delayed follow-up of
some patients beyond 2 years. Kaplan-Meier analysis further
showed that results were similar when patients were addi-
tionally censored at the time of study drug discontinuation,
with a 2-year incidence of 20%, with no significant differ-
ence between warfarin and ASA (26% vs. 15%, p  0.36).
When the analysis was restricted to those thromboses
associated with a clinical presentation, the overall incidence
at 2 years was 7%, with no significant difference between
warfarin and ASA (6% vs. 8%, p  0.80). A post hoc
analysis, which was not pre-specified, of the warfarin group
only showed that patients with a high prevalence of sub-
therapeutic INR measurements (30% of INR measure-
ments 2) had a significantly greater risk of thrombosis
(hazard ratio: 5.95; 95% confidence interval: 2.01 to 31.9;
p  0.003) than those patients well maintained in the
therapeutic range (30% of INR measurements 2).
Of the 25 initial thromboses, all were venous, with 18
(72%) detected on routine assessments, and 7 (28%) asso-
ciated with a clinical presentation with signs and symptoms
(1 with swelling/edema associated with thrombosis in the
jugular vein, 2 with swelling/edema associated with throm-
bosis in the femoral veins, 3 with dyspnea/respiratory
insufficiency associated with thrombosis in the Fontan
connection, and 1 patient with a cold/hypotensive limb
associated with thrombosis in the femoral veins). Of those
25 patients with thromboses (7 of whom had thromboses
identified in multiple locations), 20 had thromboses within
the Fontan connection, 4 within the pulmonary arteries, and
7 within other venous sites. The mean INR at the time of
detection for those receiving warfarin was 2.2. Thromboses
were noted with transthoracic echocardiography for 52% of
patients and with TEE for 84% of patients, with 20% of
intracardiac thromboses detected with TEE but not trans-
Frequency of Patient Withdrawaland Early Drug D scontinuationTable 2 Frequency of Patient Withdrawaland Early Drug Discontinuation
ASA
(n  57)
Warfarin
(n  54) p Value
Patient withdrew 0 (0%) 2 (4%) 0.23
Death 1 (2%) 0 (0%) 1.00
Patient stopped study drug 2 (4%) 3 (6%) 0.68
Physician stopped study drug 3 (5%) 6 (11%) 0.49
Study drug stopped after adverse event 0 (0%) 1 (2%) 1.00
Early discontinuation for any reason 6 (11%) 12 (22%) 0.13
ASA  acetylsalicylic acid.thoracic echocardiography.Almost all detected thromboses in the 25 patients were
treated with an increase in anticoagulation; 9 were initially
treated with heparin followed by a return to their assigned
study treatment, 6 ASA patients received heparin initially
and were then crossed over to warfarin, 2 ASA patients were
directly switched to warfarin, 4 warfarin patients had their
dose increased (1 of whom also initially received heparin),
and 1 patient required thrombolytic agents. Only 3 patients
had no change in management related to the detected
thrombosis.
Recurrent thrombosis. Thrombosis recurred in 7 patients
(28%), despite some increase in anticoagulation therapy
after the initial thrombosis. Acute treatment after the initial
episode was unfractionated heparin for 4 patients and
unfractionated heparin with thrombolytic agents for 1
patient with a clinical presentation (this patient later died of
multiorgan failure unrelated to the thrombosis or thrombo-
lytic agent). Subsequent maintenance therapy for patients
originally receiving ASA was warfarin for 2 patients, 1
patient remained on ASA only, and 1 patient was changed
from ASA to low molecular weight heparin. All 3 patients
on warfarin at the time of the initial thrombus subsequently
had their target INR range increased from 2.5 to 3.5. All
had a thrombus located within the Fontan connection, with
3 within additional venous sites. Recurrent thromboses were
asymptomatic in 6 patients.
Adverse events. One late death occurred in a patient
assigned to ASA who had a recurrent thrombosis and went
on to have a complicated surgery for Fontan revision, and
multiorgan failure subsequently developed. One patient
assigned to warfarin required Fontan takedown after an
initial thrombosis, and pulmonary hypertension and collat-
erals vessels subsequently developed.
There were 2 major bleeding events, with 1 patient
having massive cerebral hemorrhage as previously described
occurring before study drug had been started. The second
patient was assigned to warfarin and presented with gastro-
intestinal bleeding and bruising and was noted to have an
INR of 11.9; the patient was treated with vitamin K and
required multiple blood transfusions. Minor bleeding was
more prevalent for those taking warfarin versus ASA for all
locations, with 33% of those taking warfarin and 14% taking
ASA having at least 1 minor bleeding episode (p  0.03)
(Table 3). For those taking warfarin, the median INR at
assessments was 2.1 to 2.3, with 45% of readings within the
recommended therapeutic range of 2 to 3, 41% below target,
and 14% above target. One third of the patients had 30%
of warfarin levels above 2. Extreme increases in the INR
were noted, but were infrequent (Table 3).
Discussion
Fontan surgery is the definitive palliative procedure for uni-
ventricular hearts and is being performed with increasing
frequency (14). Fontan surgery provides stable cardiovascular
hemodynamics that has been shown to be compatible with
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August 2, 2011:645–51 RCT of Thromboprophylaxis After Fontangood-quality long-term survival (5–7,15). However, thrombo-
sis remains a major complication both early and late after
Fontan surgery (5,8,12). Currently, most pediatric cardiac
surgical units prescribe primary thromboprophylaxis with ei-
ther warfarin or ASA for varying durations after Fontan
surgery; however, the relative efficacy of these approaches has
never been compared prospectively (12). This study is a
prospective, multicenter, randomized, controlled trial compar-
ing warfarin with ASA as primary thromboprophylaxis after
Fontan surgery. The cumulative thrombosis rate was 23% in
the first 2 years post-surgery. Despite the finding that there
was no difference between warfarin and ASA, the event rate
was not trivial and as such supports our decision not to include a
Figure 2 Flow Chart of Patient Withdrawal and Events for Patie
(A) Of 57 patients randomized to acetylsalicylic acid (ASA), 1 patient prematurely
events, 8 (14%) experienced venous thrombotic events (1 clinical/7 routine) witho
domized to warfarin, 2 patients prematurely withdrew from the study, 39 (72%) co
thrombotic events (2 clinical/8 routine) without recurrence, and 3 (6%) (1 clinical/
recurrent venous thrombotic event; recurrent VTE [C]  clinical recurrent venous thnontreatment group in this study. Novel approaches are re-quired to reduce the frequency of thrombosis after Fontan
surgery to further enhance the survival and quality of life of this
group of patients.
Importantly, this study confirms that thrombosis remains
a major complication after Fontan surgery, despite the
improvements in surgical and supportive techniques over
the past decade. The clinical thrombosis event rate in this
study was 8%. Interestingly, there were no recorded central
nervous system thromboembolic events in this study, despite
studies previously reporting stroke rates as high as 19% after
Fontan surgery (8). Children in our study did not undergo
routine central nervous system imaging, so whether clini-
cally silent events occurred is unknown. The use of routine
andomized to ASA and Warfarin
ew from the study, 44 (77%) completed the study without venous thrombotic
rrence, and 4 (7%) (3 clinical/1 routine) with recurrence. (B) Of 54 patients ran-
d the study without venous thrombotic events, 10 (19%) experienced venous
ine) with recurrence. PW  premature withdrawal; recurrent VTE [R]  routine
tic event; VTE  venous thrombotic event.nts R
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relevance of asymptomatic intracardiac (Fontan circuit)
thrombosis is likely high. First, given that the cumulative
event rate was constant, thromboses that are currently
clinically silent may have progressed if untreated and caused
later clinical events. Second, the risk of embolization of
small thromboses to the central nervous system, especially in
children with open fenestrations, is likely important in
children with untreated intracardiac thrombosis (16). Third,
the Fontan circuit is dependent on low pulmonary vascular
resistance because venous return is the sole driver of pul-
monary blood flow (5). Recurrent small thromboses in the
Fontan circuit, with or without embolization to the lungs
may increase the pulmonary resistance and contribute to late
failure of the Fontan circuit. Of note, all clinicians treated
the asymptomatic thromboses when they were detected on
routine echocardiography, and this seems consistent with
current clinical practice.
The initial study design was for more patients (n  113
er group, 226 total for 80% power to detect a 15%
ifference in event rate); however, slower than anticipated
ecruitment (possibly due to the requirement of TEE, which
aused many families to decline) over a 5-year period forced
he study to stop with fewer participants. Nonetheless, with
11 patients enrolled in the study, this is the largest
rospective study of anticoagulation in Fontan patients ever
erformed, and the 95% confidence interval for the hazard
atio suggests that, at worst, the thrombotic risk with ASA
s 1.6 times that seen with warfarin, or, alternatively, the risk
ith warfarin is 3 times that seen with ASA. Given the
urden of warfarin therapy, as discussed subsequently,
linicians may argue that based on this hazard risk, in terms
f prevention of major thrombosis as a sole outcome, ASA
ay potentially be preferable to warfarin therapy. One
Figure 3 Thrombosis After Randomization
Patients classified by randomization, no censoring for drug discontinuation.
Kaplan-Meier estimate for the proportion of patients with thrombosis 2 years
after randomization was 19% (24% in patients randomized to warfarin vs. 14%
in patients randomized to aspirin). Hazard ratio for thrombosis for patients ran-
domized to warfarin vs. acetylsalicylic acid (ASA) was 1.35 (95% confidence
interval: 0.62 to 3.00), p  0.45.onsideration for the lack of treatment difference is whetherpatients receiving warfarin were adequately anticoagulated.
Of note, the mean INR at the time of thrombosis detection
for those patients taking warfarin was 2.2. Although 41% of
all warfarin measurements were below the target range, this
is not uncommon in children taking warfarin (17,18).
Whether increasing the target range for warfarin therapy
(e.g., to an INR of 2.5 to 3.5) would further reduce the risk
of thrombosis is unknown. The possibility of ASA resis-
tance may have contributed to treatment failure and was not
assessed in this study (19).
This study confirmed the findings of previous cross-
sectional studies that TEE is more sensitive than transthoracic
echocardiography for detecting thrombosis within the Fontan
circuit (9–11). This difference in sensitivity was operator
independent, in that it occurred across multiple centers and
was confirmed by independent adjudication of all echocardio-
grams. Newer imaging modalities, such as magnetic resonance
imaging, are in almost routine use and may supersede TEE for
thrombosis detection, thus, facilitating recruitment in future
trials by removing the requirement of invasive imaging modal-
ities. One of the key considerations in comparing long-term
ASA therapy with warfarin therapy is the risk of bleeding.
There was no difference in major bleeding between the
treatment regimens of this study. However, there was a marked
difference in minor bleeding, which was increased for patients
on warfarin therapy. This contributes to the assumption that
warfarin therapy imposes a considerable burden on children,
including the need for regular blood tests and potentially
lifestyle restrictions (for example, limitations on sporting activ-
ities) to minimize the risk of trauma-induced bleeding. Assess-
ing quality of life of patients randomized to warfarin compared
with ASA was beyond the scope of this study, but such data
would be most useful given the lack of difference in thrombosis
prevention between the 2 treatment regimens.
Conclusions
In summary, this study is a large multicenter, randomized
trial of thromboprophylaxis in children after Fontan surgery
Adverse Events and MonitoringTable 3 Adverse Events and Monitoring
ASA
(n  57)
Warfarin
(n  54) p Value
Bleeding events
Nose 8 (14%) 12 (26%) 0.33
Oral 1 (2%) 5 (9%) 0.11
Gastrointestinal 3 (5%) 4 (7%) 0.72
Genitourinary 2 (4%) 4 (8%) 0.43
Skin 4 (7%) 9 (17%) 0.15
Other 5 (9%) 9 (17%) 0.26
Any minor bleeding 8 (14%) 18 (33%) 0.03
Major bleed event 1 (2%) 1 (2%) 1.00
Abnormal warfarin monitoring (n  2,143)
INR 5 to 7 — 30 (1.4%) —
INR 7 to 9 — 10 (0.5%) —
INR 9 — 7 (0.3%) —ASA  acetylsalicylic acid; INR  international normalized ratio.
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demonstrated that thrombosis is a frequent problem after
Fontan surgery, despite thromboprophylaxis with either
warfarin or ASA. The cumulative risk of thrombosis is
persistent, suggesting prophylaxis should not be time lim-
ited after Fontan surgery. However, whether novel agents,
such as oral factor Xa inhibitors, or combination therapy
with both warfarin and ASA, or increased intensity anti-
platelet therapy will be more effective in reducing the
thrombosis risk will need to be the subject of future studies.
Further studies that include long-term follow-up, studies
that elucidate the mechanism of late Fontan circuit failure,
and studies that determine the long-term neurological
outcome will be important to help justify the duration and
intensity of primary thromboprophylaxis. The potential
long-term damage due to microvascular thromboemboli to
either the pulmonary or systemic circulation remains un-
clear. Whether regular routine TEE (or other imaging
modalities) should be performed is also a question requiring
further study; however, it is reasonable to conclude that all
available evidence now supports TEE as being more sensi-
tive than transthoracic echocardiography for Fontan circuit
thrombosis detection. Our study demonstrates the feasibil-
ity of undertaking multicenter, prospective studies of med-
ical therapy in children with uncommon and heterogeneous
cardiac malformations. This should be the first of many
such studies that will be required to optimize the medical
management of children with univentricular physiology
because survival into adulthood for these children is now
expected. The challenge is to maximize their life potential.
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